On September 3, 2024, Zynex, a medical technology company known for its non-invasive pain management and rehabilitation devices, announced the FDA clearance of its new TensWave device. Designed for prescription use, the TensWave offers a portable and user-friendly solution for pain relief through transcutaneous electrical nerve stimulation (TENS) therapy. This device aims to provide effective, medication-free pain relief for both chronic and acute pain conditions, aligning with Zynex's tradition of innovation in pain management.
The TensWave complements Zynex’s existing product line, including the NexWave electrotherapy device, which utilizes Interferential current. While NexWave remains a preferred choice for comprehensive electrotherapy, TensWave addresses a specific market need for TENS therapy devices that meet insurance reimbursement criteria. The introduction of TensWave expands Zynex’s product portfolio, supporting patients with various pain management needs while reinforcing the company's commitment to enhancing patient outcomes through advanced medical technology.
